Loading...
XNASREGN
Market cap77bUSD
Dec 23, Last price  
715.13USD
1D
1.89%
1Q
-31.63%
Jan 2017
94.81%
Name

Regeneron Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:REGN chart
P/E
19.55
P/S
5.89
EPS
36.58
Div Yield, %
0.00%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
14.34%
Revenues
13.12b
+7.76%
174,017,00066,193,00063,447,000125,024,000238,457,000379,268,000459,074,000445,824,0001,378,477,0002,104,745,0002,819,557,0004,103,728,0004,860,427,0005,872,227,0006,710,800,0007,863,400,0008,497,100,00016,071,700,00012,172,900,00013,117,200,000
Net income
3.95b
-8.87%
41,699,000-95,446,000-102,337,000-105,600,000-82,710,000-67,830,000-104,468,000-221,760,000750,269,000424,362,000348,074,000636,056,000895,522,0001,198,511,0002,444,400,0002,115,800,0003,513,200,0008,075,300,0004,338,400,0003,953,600,000
CFO
4.59b
-8.39%
-16,909,000-30,296,00023,075,00027,372,000-89,086,000-72,230,00096,344,000-141,682,000-74,615,000588,596,000752,435,0001,330,780,0001,485,900,0001,307,100,0002,195,100,0002,430,000,0002,618,100,0007,081,300,0005,014,900,0004,594,000,000
Earnings
Jan 31, 2025

Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
URL
https://www.regeneron.com/
IPO date
Apr 02, 1991
Employees
12,256
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,117,200
7.76%
12,172,900
-24.26%
16,071,700
89.14%
Cost of revenue
6,254,800
5,152,900
5,345,600
Unusual Expense (Income)
NOPBT
6,862,400
7,020,000
10,726,100
NOPBT Margin
52.32%
57.67%
66.74%
Operating Taxes
245,700
520,400
1,250,500
Tax Rate
3.58%
7.41%
11.66%
NOPAT
6,616,700
6,499,600
9,475,600
Net income
3,953,600
-8.87%
4,338,400
-46.28%
8,075,300
129.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,790,100)
(1,009,000)
(1,005,800)
BB yield
1.79%
1.23%
1.42%
Debt
Debt current
720,000
719,700
Long-term debt
3,422,900
3,421,400
3,419,400
Deferred revenue
126,700
69,800
515,300
Other long-term liabilities
854,100
(128,000)
680,200
Net debt
(12,818,400)
(15,599,100)
(15,231,600)
Cash flow
Cash from operating activities
4,594,000
5,014,900
7,081,300
CAPEX
(590,100)
(551,900)
Cash from investing activities
(3,185,100)
(3,784,600)
(5,384,700)
Cash from financing activities
(1,790,100)
(1,009,000)
(1,005,800)
FCF
6,478,800
6,273,200
9,645,800
Balance
Cash
10,844,800
14,334,100
12,532,700
Long term investments
5,396,500
5,406,400
6,838,000
Excess cash
15,585,440
19,131,855
18,567,115
Stockholders' equity
27,179,500
23,068,000
18,942,200
Invested Capital
14,071,360
6,895,045
4,490,285
ROIC
63.12%
114.17%
161.81%
ROCE
23.14%
26.91%
47.93%
EV
Common stock shares outstanding
113,700
113,500
112,200
Price
878.29
21.73%
721.49
14.25%
631.52
30.72%
Market cap
99,861,573
21.95%
81,889,115
15.57%
70,856,544
27.43%
EV
87,043,173
66,290,015
55,624,944
EBITDA
7,283,400
7,361,400
11,012,300
EV/EBITDA
11.95
9.01
5.05
Interest
73,000
59,400
57,300
Interest/NOPBT
1.06%
0.85%
0.53%